Table 1. Sensitivity analysis: threshold level for parameters tested at which RDTs are preferable to presumptive treatment at 5% and 40% malaria prevalence among febrile outpatients.
| Parameters tested | Threshold level at which RDTs are preferable to presumptive treatment |
||||
|---|---|---|---|---|---|
| 50% certainty |
95% certainty |
||||
| 5% malaria prevalence | 40% malaria prevalence | 5% malaria prevalence | 40% malaria prevalence | ||
| Cost of RDT (US$ 0–4) | Any cost | Any cost | Any cost | < US$ 2.30 | |
| Cost of an adult dose of ACT (US$ 0–4) | Any cost | Any cost | Any cost | > US$ 0.20 | |
| Adherence to ACT (0–100%) | Any level | Any level | Any level | Any level | |
| Adherence to antibiotic (0–100%) | Any level | > 4% | > 25% | > 39% | |
| Probability that non-malarial febrile illness is bacterial (0–100%) | Any level | > 4% | > 20% | > 23% | |
| Probability that patient diagnosed negative for malaria receives antibiotica (0–100%) | Any level | Any level | Any level | > 23% | |
| Probability that a patient with bacterial infection became severe (≥ 5 years: 10–25%) (< 5 years: 20–40%) | Any level | Any level | Any level | Any level | |
| Proportion of presenting population 5 years old or over (0–100%) | Any level | Any level | Any level | Any level | |
| Valuation of a DALY averted (US$ 0–500) | Any value | Any value | > US$ 48 | > US$ 70 | |
ACT, artemisinin-based combination therapy; DALY, disability-adjusted life year; RDT, rapid diagnostic test. a When less than 100%, we assumed that antibiotics were randomly allocated to patients with non-malarial febrile illness.